Literature DB >> 28713674

Intraoperative adjuncts for malignant pleural mesothelioma.

Warren Ho Chan1, David J Sugarbaker1, Bryan M Burt1.   

Abstract

Malignant pleural mesothelioma (MPM) is a rapidly fatal disease. Multimodality surgically based therapies may extend survival in select patients, however, local relapse after resection is common. Novel intraoperative adjunctive therapies including heated intraoperative chemotherapy (HIOC), heated intraoperative povidone-iodine (PVP-I), and photodynamic therapy (PDT) target micrometastatic disease and aim to improve local control. This review details the most recent studies and trials of HIOC, heated intraoperative PVP-I, and PDT, this aims to provide an update on some of the most promising intraoperative adjuncts for patients with MPM.

Entities:  

Keywords:  Malignant pleural mesothelioma (MPM); heated intraoperative chemotherapy (HIOC); heated intraoperative povidone-iodine (PVP-I); photodynamic therapy (PDT)

Year:  2017        PMID： 28713674      PMCID： PMC5504117          DOI： 10.21037/tlcr.2017.05.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  42 in total

1.  Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.

Authors:  Loïc Lang-Lazdunski; Andrea Bille; Rohit Lal; Paul Cane; Emma McLean; David Landau; Jeremy Steele; James Spicer
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

Review 2.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

3.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

Authors:  D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

4.  Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.

Authors:  David J Sugarbaker; Ritu R Gill; Beow Y Yeap; Andrea S Wolf; Marcelo C DaSilva; Elizabeth H Baldini; Raphael Bueno; William G Richards
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-21       Impact factor: 5.209

5.  Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.

Authors:  H Schouwink; E T Rutgers; J van der Sijp; H Oppelaar; N van Zandwijk; R van Veen; S Burgers; F A Stewart; F Zoetmulder; P Baas
Journal:  Chest       Date:  2001-10       Impact factor: 9.410

6.  Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma.

Authors:  H I Pass; B K Temeck; K Kranda; G Thomas; A Russo; P Smith; W Friauf; S M Steinberg
Journal:  Ann Surg Oncol       Date:  1997-12       Impact factor: 5.344

7.  Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.

Authors:  Joseph S Friedberg; Melissa J Culligan; Rosemarie Mick; James Stevenson; Stephen M Hahn; Daniel Sterman; Salman Punekar; Eli Glatstein; Keith Cengel
Journal:  Ann Thorac Surg       Date:  2012-05       Impact factor: 4.330

8.  A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.

Authors:  Lambros Zellos; William G Richards; Leah Capalbo; Michael T Jaklitsch; Lucian R Chirieac; Bruce E Johnson; Raphael Bueno; David J Sugarbaker
Journal:  J Thorac Cardiovasc Surg       Date:  2009-02       Impact factor: 5.209

9.  Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up.

Authors:  T L Moskal; T J Dougherty; J D Urschel; J G Antkowiak; A M Regal; D L Driscoll; H Takita
Journal:  Ann Thorac Surg       Date:  1998-10       Impact factor: 4.330

10.  Clinical pharmacology of intraperitoneal cisplatin.

Authors:  J A Lopez; J G Krikorian; S D Reich; R D Smyth; F H Lee; B F Issell
Journal:  Gynecol Oncol       Date:  1985-01       Impact factor: 5.482
View more
  7 in total

Review 1.  The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.

Authors:  Pietro Bertoglio; Vittorio Aprile; Marcello Carlo Ambrogi; Alfredo Mussi; Marco Lucchi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 2.  Landmark Trials in the Surgical Management of Mesothelioma.

Authors:  Taylor Kantor; Elliot Wakeam
Journal:  Ann Surg Oncol       Date:  2021-01-31       Impact factor: 5.344

3.  A Clinical Trial of TumorGlow to Identify Residual Disease During Pleurectomy and Decortication.

Authors:  Jarrod D Predina; Andrew D Newton; Christopher Corbett; Leilei Xia; Michael Shin; Lydia Frenzel Sulfyok; Olugbenga T Okusanya; Keith A Cengel; Andrew Haas; Leslie Litzky; John C Kucharczuk; Sunil Singhal
Journal:  Ann Thorac Surg       Date:  2018-07-17       Impact factor: 4.330

4.  Povidone-iodine results in rapid killing of thymic epithelial tumour cells through cellular fixation†.

Authors:  Hyun-Sung Lee; Hee-Jin Jang; Eric M Lo; Cynthia Y Truong; Shawn S Groth; Joseph S Friedberg; David J Sugarbaker; Bryan M Burt
Journal:  Interact Cardiovasc Thorac Surg       Date:  2019-03-01

5.  Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.

Authors:  Luca Ampollini; Elisabetta Barocelli; Andrea Cavazzoni; Piergiorgio Petronini; Claudio Mucchino; Anna Maria Cantoni; Fabio Leonardi; Luigi Ventura; Stefano Barbieri; Paolo Colombo; Antonella Fusari; Paolo Carbognani; Michele Rusca; Fabio Sonvico
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 6.  An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma.

Authors:  Alexander Davis; Helen Ke; Steven Kao; Nick Pavlakis
Journal:  Lung Cancer (Auckl)       Date:  2022-03-02

7.  Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience.

Authors:  Francesco Falanga; Pietro Rinaldi; Cristiano Primiceri; Chandra Bortolotto; Olga Oneta; Francesco Agustoni; Patrizia Morbini; Laura Saracino; Dimitrios Eleftheriou; Federico Sottotetti; Giulia Maria Stella
Journal:  Thorac Cancer       Date:  2022-09-02       Impact factor: 3.223
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.